| abstract |
REFERS TO COMPOUNDS DERIVED FROM [1,2,4] TRIAZOLE OF FORMULA (I), WHERE R1 IS METHYL, HALOGEN AND CYANE; R2 IS H AND FLUORINE; R3 IS H AND ALKYL (C1-C3); R4 IS H AND ALKYL (C1-C3); R5 IS (C1-C3) ALKYL AND CYCLOPROPYL; X IS A GROUP a), b) OR c); Z IS e), f), AMONG OTHERS; R6 IS H, (C1-C3) ALKYL, (C1-C3) HALOALKYL, AMONG OTHERS; R7 IS H, ALKYL (C1-C3), AMONG OTHERS. THEY ARE SELECTED: 4- (5 - {(1R) -1- [5- (3-CHLOROPHENYL) ISOXAZOL-3-IL] ETOXY} -4-METHYL-4H-1,2,4-TRIAZOL-3-IL) -1-METHYLPYRIDIN-2 (1H) -ONE, 4- (5 - {(1R) -1- [5- (3-CHLOROPHENYL) -1,2,4-OXADIAZOL-3-IL] ETOXY} -4- METHYL-4H-1,2,4-TRIAZOL-3-IL) -1-METHYLPYRIMIDIN-2 (1H) -ONE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. THESE COMPOUNDS ARE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS (mGluRs), AND PRESENT A PREDOMINANTLY PERIPHERAL ACTION, BEING USEFUL IN THE TREATMENT OF ESOPHAGEAL REFLUX, PAIN, ANXIETY, COLON SYNDROME (IRRITABLE IBS) |